IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: BIOLOGICAL: IMP321
Sponsor: Immutep S.A.S.
Collaborators: Umanis